0000000000115974

AUTHOR

Martine Laville

showing 4 related works from this author

PIK3R1 Mutations Cause Syndromic Insulin Resistance with Lipoatrophy

2013

International audience; Short stature, hyperextensibility of joints and/or inguinal hernia, ocular depression, Rieger anomaly, and teething delay (SHORT) syndrome is a developmental disorder with an unknown genetic cause and hallmarks that include insulin resistance and lack of subcutaneous fat. We ascertained two unrelated individuals with SHORT syndrome, hypothesized that the observed phenotype was most likely due to de novo mutations in the same gene, and performed whole-exome sequencing in the two probands and their unaffected parents. We then confirmed our initial observations in four other subjects with SHORT syndrome from three families, as well as 14 unrelated subjects presenting wi…

ProbandEXPRESSIONmedicine.medical_specialty030209 endocrinology & metabolismBiologymedicine.disease_causeMICE LACKINGShort stature03 medical and health sciencesHYPOGLYCEMIA0302 clinical medicineInsulin resistancePIK3R1Internal medicineReportmedicineGeneticsKINASEGenetics(clinical)LipoatrophyGenetics (clinical)030304 developmental biology0303 health sciencesMutationAKT2[SDV.GEN]Life Sciences [q-bio]/GeneticsRECEPTORmedicine.disease3-KINASE3. Good healthInsulin receptorEndocrinologyAUTOPHOSPHORYLATIONSHORT syndromebiology.proteinSKELETAL-MUSCLEGROWTHmedicine.symptom[ SDV.GEN ] Life Sciences [q-bio]/Genetics
researchProduct

Salivary composition in obese vs normal-weight subjects: towards a role in postprandial lipid metabolism?

2015

In the pathophysiological context of obesity, oral exposure to dietary fat can modulate lipid digestion and absorption but underlying in-mouth mechanisms have not been clearly identified. Therefore we tested the hypothesis that salivary components related to dietary fat sensitivity would differ according to BMI and postprandial lipid metabolism in young men. Saliva was collected from 9 normal-weight (BMI=22.3±0.5 kg/m2) and 9 non-morbid obese (BMI=31.7±0.3 kg/m2) men before a 8 h-postprandial metabolic exploration test involving the consumption of a 40 g fat-meal, in which obese subjects revealed a delayed postprandial lipid metabolism. Nine salivary characteristics (flow, protein content, …

AdultBlood GlucoseMaleSalivamedicine.medical_specialtyproteolysis030309 nutrition & dieteticsEndocrinology Diabetes and Metabolism[ SDV.AEN ] Life Sciences [q-bio]/Food and NutritionMedicine (miscellaneous)Context (language use)salivary compositionBody Mass Index03 medical and health sciencesThinnessInternal medicinelipid metabolismmedicineLipolysisHumansObesitySalivaMeals030304 developmental biology0303 health sciencesNutrition and Dieteticsobesebusiness.industryLipid metabolism[ SDV.MHEP.EM ] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismPostprandial PeriodDietary Fats3. Good healthPostprandialEndocrinologylipolysismedicine.symptombusinessEnergy MetabolismWeight gainBody mass indexLipid digestion[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition
researchProduct

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-…

2017

Background: \ud Liraglutide 3·0 mg was shown to reduce bodyweight and improve glucose metabolism after the 56-week period of this trial, one of four trials in the SCALE programme. In the 3-year assessment of the SCALE Obesity and Prediabetes trial we aimed to evaluate the proportion of individuals with prediabetes who were diagnosed with type 2 diabetes.\ud \ud Methods: \ud In this randomised, double-blind, placebo-controlled trial, adults with prediabetes and a body-mass index of at least 30 kg/m2, or at least 27 kg/m2 with comorbidities, were randomised 2:1, using a telephone or web-based system, to once-daily subcutaneous liraglutide 3·0 mg or matched placebo, as an adjunct to a reduced-…

Blood GlucoseMaleEXENATIDEType 2 diabetes030204 cardiovascular system & hematologyBody Mass Indexlaw.inventionPlacebosImpaired glucose toleranceMELLITUS3.0 MG0302 clinical medicineRandomized controlled trialGlucagon-Like Peptide 1lawPREVENTION PROGRAM OUTCOMESPrediabetesPREVENTION PROGRAM OUTCOMES; IMPAIRED GLUCOSE-TOLERANCE; LIFE-STYLE; CLINICAL-TRIAL; OBESE SUBJECTS; 3.0 MG; REGRESSION; EXENATIDE; MELLITUSSubcutaneousMedicine (all)General MedicineMiddle AgedAdult; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus Type 2; Double-Blind Method; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Injections Subcutaneous; Liraglutide; Male; Middle Aged; Obesity; Placebos; Prediabetic State; Risk Reduction Behavior; Treatment Outcome; Weight Loss3. Good healthTreatment OutcomeFemaleLIFE-STYLEType 2OBESE SUBJECTSmedicine.drugAdultmedicine.medical_specialtyInjections Subcutaneous030209 endocrinology & metabolismPlaceboIncretinsGlucagon-Like Peptide-1 ReceptorInjectionsCLINICAL-TRIALPrediabetic State03 medical and health sciencesIMPAIRED GLUCOSE-TOLERANCEDouble-Blind MethodDiabetes mellitusInternal medicineWeight LossREGRESSIONDiabetes MellitusmedicineHumansHypoglycemic AgentsObesityLiraglutidebusiness.industryBody WeightLiraglutidemedicine.diseaseClinical trialEndocrinologyDiabetes Mellitus Type 2Human medicinebusinessRisk Reduction Behavior[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyThe Lancet
researchProduct

40(th) EASD Annual Meeting of the European Association for the Study of Diabetes : Munich, Germany, 5-9 September 2004

2004

0303 health sciencesmedicine.medical_specialtybusiness.industryEASDEndocrinology Diabetes and MetabolismHuman physiologymedicine.disease03 medical and health sciences0302 clinical medicineDiabetes mellitusFamily medicineInternal MedicineMedicinebusiness030217 neurology & neurosurgery030304 developmental biology
researchProduct